疗效和安全性-话题@MedSci

#疗效和安全性#

431篇内容 | 2573人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1721202, encodeId=1c661e212027b, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Front Pharmacol：益生菌联合中药治疗溃疡性结肠炎的疗效和安全性, objectType=article, longId=728791, objectId=250fe2879102, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=250fe2879102, replyNumber=0, likeNumber=69, createdTime=2022-10-13, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=250fe2879102, moduleTitle=Front Pharmacol：益生菌联合中药治疗溃疡性结肠炎的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=250fe2879102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721160, encodeId=17191e2116079, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性, objectType=article, longId=295174, objectId=ce4f2951e4a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce4f2951e4a6, replyNumber=0, likeNumber=72, createdTime=2023-01-19, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce4f2951e4a6, moduleTitle=J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce4f2951e4a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721141, encodeId=774c1e21141e3, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Thorac Cancer：Anlotinib（安罗替尼）治疗小细胞肺癌伴有胸腔积液患者的疗效和安全性, objectType=article, longId=221642, objectId=5305221642d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5305221642d2, replyNumber=0, likeNumber=64, createdTime=2022-06-18, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5305221642d2, moduleTitle=Thorac Cancer：Anlotinib（安罗替尼）治疗小细胞肺癌伴有胸腔积液患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5305221642d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721107, encodeId=22881e211078b, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Eur J Cancer：GLS-010 (zimberelimab)在中国复发或难治性经典霍奇金淋巴瘤(r/r-cHL)患者中的疗效和安全性, objectType=article, longId=220097, objectId=8a2422009e45, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a2422009e45, replyNumber=0, likeNumber=58, createdTime=2022-09-15, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a2422009e45, moduleTitle=Eur J Cancer：GLS-010 (zimberelimab)在中国复发或难治性经典霍奇金淋巴瘤(r/r-cHL)患者中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a2422009e45)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721054, encodeId=88ca1e2105464, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Thorac Oncol：EGFR 突变NSCLC脑膜转移患者TKI抑制剂进展后鞘内注射培美曲塞联合地塞米松的疗效和安全性, objectType=article, longId=214414, objectId=2f7c2144147c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f7c2144147c, replyNumber=0, likeNumber=66, createdTime=2022-02-20, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f7c2144147c, moduleTitle=J Thorac Oncol：EGFR 突变NSCLC脑膜转移患者TKI抑制剂进展后鞘内注射培美曲塞联合地塞米松的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f7c2144147c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721182, encodeId=2f5d1e2118245, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lancet Oncol：转移性肾透明细胞癌的三种一线治疗方案的疗效和安全性, objectType=article, longId=723824, objectId=cc6fe23824f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc6fe23824f3, replyNumber=0, likeNumber=83, createdTime=2022-09-16, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc6fe23824f3, moduleTitle=Lancet Oncol：转移性肾透明细胞癌的三种一线治疗方案的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc6fe23824f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721119, encodeId=e97c1e21119d1, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性, objectType=article, longId=220795, objectId=abf7220e9596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abf7220e9596, replyNumber=0, likeNumber=61, createdTime=2022-03-28, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abf7220e9596, moduleTitle=J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abf7220e9596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721110, encodeId=38301e211105f, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Front Oncol：贝叶斯网状Meta分析比较ALK阳性NSCLC患者一线治疗方案的疗效和安全性, objectType=article, longId=220334, objectId=0e9e2203349a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e9e2203349a, replyNumber=0, likeNumber=111, createdTime=2022-01-10, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e9e2203349a, moduleTitle=Front Oncol：贝叶斯网状Meta分析比较ALK阳性NSCLC患者一线治疗方案的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e9e2203349a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721124, encodeId=a66d1e211242a, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ann Rheum Dis：瑞莎珠单抗治疗对活动性银屑病关节炎的疗效和安全性分析, objectType=article, longId=221074, objectId=c0212210e40d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0212210e40d, replyNumber=0, likeNumber=88, createdTime=2022-05-19, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0212210e40d, moduleTitle=Ann Rheum Dis：瑞莎珠单抗治疗对活动性银屑病关节炎的疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0212210e40d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721096, encodeId=bae71e2109637, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Mayo Clin Proc：富含血小板血浆对慢性伤口愈合的疗效和安全性, objectType=article, longId=218972, objectId=9fd42189e2f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fd42189e2f2, replyNumber=0, likeNumber=94, createdTime=2022-09-04, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fd42189e2f2, moduleTitle=Mayo Clin Proc：富含血小板血浆对慢性伤口愈合的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fd42189e2f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721178, encodeId=21ac1e2117824, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Immunother Cancer：卡瑞利珠单抗+化疗作为局部晚期食管癌术前辅助治疗的疗效和安全性, objectType=article, longId=301810, objectId=b131301810c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b131301810c5, replyNumber=0, likeNumber=81, createdTime=2023-01-18, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b131301810c5, moduleTitle=J Immunother Cancer：卡瑞利珠单抗+化疗作为局部晚期食管癌术前辅助治疗的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b131301810c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721104, encodeId=c6dc1e21104a1, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Clinical Lung Cancer：晚期非鳞状非小细胞肺癌(NSQ-NSCLC)患者化疗后培美曲塞+/-抗VEGF维持的疗效和安全性, objectType=article, longId=219975, objectId=348e2199e529, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=348e2199e529, replyNumber=0, likeNumber=78, createdTime=2022-07-24, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=348e2199e529, moduleTitle=Clinical Lung Cancer：晚期非鳞状非小细胞肺癌(NSQ-NSCLC)患者化疗后培美曲塞+/-抗VEGF维持的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=348e2199e529)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721125, encodeId=c8b71e21125e6, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Front Oncol：SMART+顺铂（CDDP）/S1治疗老年食管鳞状细胞癌（ESCC）患者的疗效和安全性, objectType=article, longId=221107, objectId=ae7022110e3c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae7022110e3c, replyNumber=0, likeNumber=64, createdTime=2022-05-09, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae7022110e3c, moduleTitle=Front Oncol：SMART+顺铂（CDDP）/S1治疗老年食管鳞状细胞癌（ESCC）患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae7022110e3c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721047, encodeId=1bec1e2104721, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ann Oncol: Ribociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性：III期临床研究MONALEESA-3的结果更新, objectType=article, longId=213384, objectId=18202133844d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18202133844d, replyNumber=0, likeNumber=88, createdTime=2021-10-04, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18202133844d, moduleTitle=Ann Oncol: Ribociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性：III期临床研究MONALEESA-3的结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18202133844d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721062, encodeId=876e1e2106229, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ann Rheum Dis：布罗达单抗对中轴型脊柱关节炎的疗效和安全性, objectType=article, longId=215590, objectId=01e121559085, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01e121559085, replyNumber=0, likeNumber=134, createdTime=2021-10-05, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01e121559085, moduleTitle=Ann Rheum Dis：布罗达单抗对中轴型脊柱关节炎的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01e121559085)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721138, encodeId=9b0a1e21138b8, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Eur J Cancer：Nivolumab联合多西他赛治疗未经化疗的转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, objectType=article, longId=221438, objectId=433422143891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=433422143891, replyNumber=0, likeNumber=67, createdTime=2022-08-28, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=433422143891, moduleTitle=Eur J Cancer：Nivolumab联合多西他赛治疗未经化疗的转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=433422143891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721149, encodeId=e3461e21149b7, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Chin J Cancer Res：中肿徐瑞华教授团队IV期观察性研究：评估中国转移性结直肠癌使用化疗联合贝伐珠单抗治疗的真实世界疗效和安全性, objectType=article, longId=292555, objectId=6a7d292555c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a7d292555c6, replyNumber=0, likeNumber=77, createdTime=2022-08-24, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a7d292555c6, moduleTitle=Chin J Cancer Res：中肿徐瑞华教授团队IV期观察性研究：评估中国转移性结直肠癌使用化疗联合贝伐珠单抗治疗的真实世界疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a7d292555c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721158, encodeId=63b31e211582a, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ann Oncol：TNBC患者标准新辅助化疗中加入卡铂联合或不联合veliparib（维拉帕利）的疗效和安全性, objectType=article, longId=295073, objectId=a9a02950e37b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9a02950e37b, replyNumber=0, likeNumber=68, createdTime=2022-05-23, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9a02950e37b, moduleTitle=Ann Oncol：TNBC患者标准新辅助化疗中加入卡铂联合或不联合veliparib（维拉帕利）的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9a02950e37b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721065, encodeId=d4431e21065ca, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Photodiagnosis Photodyn Ther：多发性面部扁平疣的儿童采用常规与日光光动力疗法的疗效和安全性, objectType=article, longId=216326, objectId=49702163262f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49702163262f, replyNumber=0, likeNumber=94, createdTime=2022-03-20, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49702163262f, moduleTitle=Photodiagnosis Photodyn Ther：多发性面部扁平疣的儿童采用常规与日光光动力疗法的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49702163262f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721084, encodeId=66b81e21084b3, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lancet Respir Med：西地那非与吡非尼酮对特发性纤维化相关的肺动脉高压患者中的疗效和安全性评估, objectType=article, longId=217949, objectId=9c9021e94927, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c9021e94927, replyNumber=0, likeNumber=76, createdTime=2022-06-28, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c9021e94927, moduleTitle=Lancet Respir Med：西地那非与吡非尼酮对特发性纤维化相关的肺动脉高压患者中的疗效和安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c9021e94927)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

疗效和安全性

2020-05-29

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Front Pharmacol：益生菌联合中药治疗溃疡性结肠炎的疗效和安全性

2022-10-13

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性

2023-01-19

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Thorac Cancer：Anlotinib（安罗替尼）治疗小细胞肺癌伴有胸腔积液患者的疗效和安全性

2022-06-18

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Eur J Cancer：GLS-010 (zimberelimab)在中国复发或难治性经典霍奇金淋巴瘤(r/r-cHL)患者中的疗效和安全性

2022-09-15

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Thorac Oncol：EGFR 突变NSCLC脑膜转移患者TKI抑制剂进展后鞘内注射培美曲塞联合地塞米松的疗效和安全性

2022-02-20

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Lancet Oncol：转移性肾透明细胞癌的三种一线治疗方案的疗效和安全性

2022-09-16

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性

2022-03-28

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Front Oncol：贝叶斯网状Meta分析比较ALK阳性NSCLC患者一线治疗方案的疗效和安全性

2022-01-10

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Ann Rheum Dis：瑞莎珠单抗治疗对活动性银屑病关节炎的疗效和安全性分析

2022-05-19

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Mayo Clin Proc：富含血小板血浆对慢性伤口愈合的疗效和安全性

2022-09-04

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Immunother Cancer：卡瑞利珠单抗+化疗作为局部晚期食管癌术前辅助治疗的疗效和安全性

2023-01-18

智慧医人 (审核中...)

前往app查看评论内容

#疗效和安全性#

Clinical Lung Cancer：晚期非鳞状非小细胞肺癌(NSQ-NSCLC)患者化疗后培美曲塞+/-抗VEGF维持的疗效和安全性

2022-07-24

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Front Oncol：SMART+顺铂（CDDP）/S1治疗老年食管鳞状细胞癌（ESCC）患者的疗效和安全性

2022-05-09

智慧医人 (审核中...)

前往app查看评论内容

#疗效和安全性#

Ann Oncol: Ribociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性：III期临床研究MONALEESA-3的结果更新

2021-10-04

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Ann Rheum Dis：布罗达单抗对中轴型脊柱关节炎的疗效和安全性

2021-10-05

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Eur J Cancer：Nivolumab联合多西他赛治疗未经化疗的转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性

2022-08-28

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Chin J Cancer Res：中肿徐瑞华教授团队IV期观察性研究：评估中国转移性结直肠癌使用化疗联合贝伐珠单抗治疗的真实世界疗效和安全性

2022-08-24

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Ann Oncol：TNBC患者标准新辅助化疗中加入卡铂联合或不联合veliparib（维拉帕利）的疗效和安全性

2022-05-23

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Photodiagnosis Photodyn Ther：多发性面部扁平疣的儿童采用常规与日光光动力疗法的疗效和安全性

2022-03-20

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Lancet Respir Med：西地那非与吡非尼酮对特发性纤维化相关的肺动脉高压患者中的疗效和安全性评估

2022-06-28

科室
- - 订阅+
  - 更多科室
工具
服务